News briefing: FDA lifts a hold on Poseida study; Decibel adopts 2-AAV approach to hearing loss; AstraZeneca partners on combos, again
A little more than 2 months ago, shares of newly public Poseida Therapeutics $PSTX cratered after the biotech reported that a patient death …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
